Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2015 (2015), Article ID 186740, 6 pages
http://dx.doi.org/10.1155/2015/186740
Research Article

Current Patterns of Management of Advanced Prostate Cancer in Routine Clinical Practice in Spain

1Department of Urology, Hospital Clínic, Carrer Villarroel 170, 08036 Barcelona, Spain
2Department of Urology, Hospital Universitario Puerta de Hierro, Calle Manuel de Falla, 1, Majadahonda, 28222 Madrid, Spain
3Department of Urology, Hospital Clínico Universitario de Santiago de Compostela, Rúa da Cantaleta 9, 15706 Santiago de Compostela, Spain

Received 9 April 2015; Accepted 16 June 2015

Academic Editor: James L. Gulley

Copyright © 2015 Maria José Ribal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. T. M. Amaral, D. Macedo, I. Fernandes, and L. Costa, “Castration-resistant prostate cancer: mechanisms, targets, and treatment,” Prostate Cancer, vol. 2012, Article ID 327253, 11 pages, 2012. View at Publisher · View at Google Scholar
  2. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Shapiro and B. Tareen, “Current and emerging treatments in the management of castration-resistant prostate cancer,” Expert Review of Anticancer Therapy, vol. 12, no. 7, pp. 951–964, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Molina and A. Belldegrun, “Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling,” Journal of Urology, vol. 185, no. 3, pp. 787–794, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. C. N. Sternberg, E. S. Baskin-Bey, M. Watson, A. Worsfold, A. Rider, and B. Tombal, “Treatment patterns and characteristics of European patients with castration-resistant prostate cancer,” BMC Urology, vol. 13, no. 1, article 58, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Kirby, C. Hirst, and E. D. Crawford, “Characterising the castration-resistant prostate cancer population: a systematic review,” International Journal of Clinical Practice, vol. 65, no. 11, pp. 1180–1192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. I. F. Tannock, R. de Wit, W. R. Berry et al., “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer,” The New England Journal of Medicine, vol. 351, no. 15, pp. 1502–1512, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. European Association of Urology, “Guidelines on Prostate Cancer 2013,” http://uroweb.org/wp-content/uploads/09_Prostate_Cancer_LR.pdf.
  9. A. Heidenreich, P. J. Bastian, J. Bellmunt et al., “EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer,” European Urology, vol. 65, no. 2, pp. 467–479, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. L. Mohler, P. W. Kantoff, A. J. Armstrong et al., “Prostate cancer, version 1.2014,” Journal of the National Comprehensive Cancer Network, vol. 11, no. 12, pp. 1471–1479, 2013. View at Google Scholar
  11. A. Heidenreich, D. Porres, C. Piper, A. K. Thissen, and D. Pfister, “Metastatic castration-resistant prostate cancer: integrating new learnings to optimise treatment outcomes,” Minerva Urologica e Nefrologica, vol. 65, no. 3, pp. 171–187, 2013. View at Google Scholar · View at Scopus
  12. N. D. Shore, “Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?” Prostate Cancer and Prostatic Diseases, vol. 16, no. 1, pp. 1–6, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. E. D. Crawford, “The role of the urologist in treating patients with hormone-refractory prostate cancer,” Reviews in Urology, vol. 5, supplement 2, pp. S48–S52, 2003. View at Google Scholar
  14. N. Mottet, J. Bellmunt, M. Bolla et al., “EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer,” European Urology, vol. 59, no. 4, pp. 572–583, 2011. View at Publisher · View at Google Scholar
  15. European Association of Urology, Guidelines on Prostate Cancer, 2011, http://uroweb.org/wp-content/uploads/08_Prostate_Cancer-September-22nd-2011.pdf.
  16. M. R. Cooperberg, J. M. Broering, and P. R. Carroll, “Time trends and local variation in primary treatment of localized prostate cancer,” Journal of Clinical Oncology, vol. 28, no. 7, pp. 1117–1123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Sharifi, J. L. Gulley, and W. L. Dahut, “Androgen deprivation therapy for prostate cancer,” Journal of the American Medical Association, vol. 294, no. 2, pp. 238–244, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Villavicencio, C. Hernández, A. Gómez et al., “Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology,” Actas Urologicas Espanolas, vol. 37, no. 6, pp. 321–323, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. S. S. Taneja, “A multidisciplinary approach to the management of hormone-refractory prostate cancer,” Reviews in Urology, vol. 5, supplement 3, pp. S85–S91, 2003. View at Google Scholar
  20. J. A. Carter and M. F. Botteman, “Health-economic review of zoledronic acid for the management of skeletal-related events in bone-metastatic prostate cancer,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 12, no. 4, pp. 425–437, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. N. W. Clarke, “Balancing toxicity and efficacy: learning from trials and treatment using antiresorptive therapy in prostate cancer,” European Urology, vol. 65, no. 2, pp. 287–288, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. J. M. Fitzpatrick, J. Bellmunt, K. Fizazi et al., “Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel,” European Journal of Cancer, vol. 50, no. 9, pp. 1617–1627, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Pokras, T. Zyczynski, M. Lees, X. Jiao, C. Blanchette, and J. Powers, “Treatment patterns after castration resistant prostate cancer (CRPC) diagnosis: a European physician survey,” Value in Health, vol. 16, no. 3, p. A1, 2013. View at Publisher · View at Google Scholar
  24. S. J. Freedland, A. Richhariya, H. Wang, K. Chung, and N. D. Shore, “Treatment patterns in patients with prostate cancer and bone metastasis among us community-based urology group practices,” Urology, vol. 80, no. 2, pp. 293–298, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. C. N. Sternberg, M. Krainer, W. K. Oh et al., “The medical management of prostate cancer: a multidisciplinary team approach,” BJU International, vol. 99, no. 1, pp. 22–27, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. J. Armstrong and D. J. George, “Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer,” Prostate Cancer and Prostatic Diseases, vol. 13, no. 2, pp. 108–116, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. D. R. Berthold, G. R. Pond, F. Soban, R. de Wit, M. Eisenberger, and I. F. Tannock, “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study,” Journal of Clinical Oncology, vol. 26, no. 2, pp. 242–245, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. G. R. Thoreson, B. A. Gayed, P. H. Chung, and G. V. Raj, “Emerging therapies in castration resistant prostate cancer,” The Canadian Journal of Urology, vol. 21, no. 2, supplement 1, pp. 98–105, 2014. View at Google Scholar
  29. C. J. Logothetis, “Treatment of castrate-resistant prostate cancer,” Journal of Urology, vol. 190, no. 2, pp. 439–440, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. H. H. Woo, “Prostate cancer: are urologists ready to manage castration-resistant disease?” Nature Reviews Urology, vol. 10, no. 3, pp. 133–134, 2013. View at Publisher · View at Google Scholar · View at Scopus